ANI Pharmaceuticals makes $540 million bid for rare disease company

ANI Pharmaceuticals has made an offer worth approximately $540 million for Sweden's Egetis Therapeutics, which develops treatments for rare diseases. HPC can identify pharmaceutical distributors, healthcare investors and specialist medical businesses interested in international partnerships and acquisitions.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.